Cargando…
PB1822: INHIBITION OF THE DNA DAMAGE RESPONSE: A POSSIBLE NEW ROUTE IN ACUTE MYELOBLASTIC LEUKEMIA TREATMENT
Autores principales: | Lapa, Beatriz, Costa, Maria Inês, Jorge, Joana, Alves, Raquel, Sarmento-Ribeiro, Ana Bela, Gonçalves, Ana Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429927/ http://dx.doi.org/10.1097/01.HS9.0000974136.14635.48 |
Ejemplares similares
-
PB1781: THERAPEUTIC POTENTIAL OF DNA DAMAGE RESPONSE IN ACUTE MYELOBLASTIC LEUKEMIA
por: Lapa, B., et al.
Publicado: (2022) -
PB1908: NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY
por: Jorge, Joana, et al.
Publicado: (2023) -
PB1841: NUCLEOLIN INTERACTS WITH NUCLEOPHOSMIN AS A PREDICTOR OF PROGNOSIS IN ACUTE MYELOBLASTIC LEUKEMIA
por: Pereira, Marta, et al.
Publicado: (2023) -
PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
por: Jorge, Joana, et al.
Publicado: (2023) -
PB1719: NIRAPARIB IN B-CELL LYMPHOID MALIGNANCIES: EXPLORING SYNTHETIC LETHALITY AS TARGET FOR THERAPY
por: Lapa, Beatriz, et al.
Publicado: (2023)